Key result
Prostate cancer is linked to a ~52% higher risk of depressive disorders versus cancer-free controls.
Why the study?
Risk factors for newly diagnosed mood disorders, including depressive and bipolar disorders, in prostate cancer patients were not well identified.
Does a diagnosis of prostate cancer increase the risk of developing mood disorders in men?
Cohort (n=25,744)
Does a diagnosis of prostate cancer increase the risk of developing mood disorders in men?
Prostate cancer diagnosis is associated with a significantly increased risk of developing depressive and bipolar disorders, with cerebrovascular disease and radiotherapy identified as potential independent risk factors.
Answers are grounded in this paper and cite their sources.
May warrant mood disorder monitoring in prostate cancer; leaves open causal links and needs prospective confirmation before practice change.
BACKGROUND: This study identified possible risk factors for newly diagnosed mood disorders, including depressive and bipolar disorders, in prostate cancer patients. METHODS: From 2000 to 2006, two cohorts were evaluated on the occurrence of mood disorder diagnosis and treatment. For the first cohort, data of patients diagnosed with prostate cancer was obtained from the Taiwan National Health Insurance (NHI) Research Database. As the second cohort, a cancer-free comparison group was matched for age, comorbidities, geographic region, and socioeconomic status. RESULTS: Final analyses involved 12,872 men with prostate cancer and 12,872 matched patients. Increased incidence of both depressive (IRR 1.52, 95% CI 1.30-1.79, P <0.001) and bipolar disorder (IRR 1.84, 95% CI 1.25-2.74, P = 0.001) was observed among patients diagnosed with prostate cancer. Multivariate matched regression models show that cerebrovascular disease (CVD) and radiotherapy treatment could be independent risk factors for developing subsequent depressive and bipolar disorders. CONCLUSION: We observed that the risk of developing newly diagnosed depressive and bipolar disorders is higher among Taiwanese prostate cancer patients. Clinicians should be aware of the possibility of increased depressive and bipolar disorders among prostate cancer patients in Taiwan. A prospective study is necessary to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2014) conducted a cohort in Prostate cancer (n=25,744). Prostate cancer vs. Cancer-free matched controls was evaluated on Newly diagnosed depressive disorder (IRR 1.52, 95% CI 1.30-1.79, p=<0.001). Prostate cancer was associated with an increased incidence of depressive (IRR 1.52; 95% CI 1.30-1.79) and bipolar disorders (IRR 1.84; 95% CI 1.25-2.74) compared to matched cancer-free controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: